Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Melanoma 17Carcinoma, Renal Cell 7Multiple Myeloma 4Recurrence 3Leukemia 3Carcinoma, Hepatocellular 3Triple Negative Breast Neoplasms 2Neoplasms 2Neoplasm Metastasis 2Lymphoma 2Breast Neoplasms 2Uveal Melanoma 1Urinary Bladder Neoplasms 1Urethral Neoplasms 1Small Cell Lung Carcinoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Peritoneal Neoplasms 1Pancreatic Neoplasms 1Oligodendroglioma 1Neoplasms, Plasma Cell 1Mycosis Fungoides 1Lymphoma, T-Cell 1Lymphoma, Follicular 1Lung Neoplasms 1Liver Neoplasms 1Liver Cirrhosis 1Leukemia-Lymphoma, Adult T-Cell 1Kidney Neoplasms 1Hepatitis C, Chronic 1Hepatitis C 1

Interventions

ledipasvir, sofosbuvir drug combination 2ledipasvir 2Ribavirin 2peginterferon alfa-2a 1daclatasvir 1Viusid 1Sofosbuvir 1Simeprevir 1Introns 1Dietary Supplements 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Hepatitis C, Chronic × Introns × Clear all
NCT00375661 2015-09-02

Low-dose Peg-interferon Plus Ribavirin (IFN/RBV) for Prevention of Hepatocellular Carcinoma (HCC) Recurrence in Patients Who Had Surgery to Remove Primary HCC

Kyoto University Hospital

Phase 4 Completed
100 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Hepatitis C, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡